Related Experiment Video
Updated: Aug 28, 2025
Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
Published on: July 28, 2013
White matter alterations in chronic MDMA use: Evidence from diffusion tensor imaging and neurofilament light chain
Josua Zimmermann1, Nicole Friedli2, Francesco Bavato2
1Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland; Neuroscience Center Zurich, ETH Zurich and University of Zurich, Zurich, Switzerland.
Abstract:
3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") is a serotonin- and noradrenaline-releasing substance, currently among the most widely used illicit substances worldwide. In animal studies, repeated exposure to MDMA has been associated with dendritic but also axonal degeneration in the brain. However, translation of the axonal findings, specifically, to humans has been repeatedly questioned and the few existing studies investigating white matter alterations in human chronic MDMA users have yielded conflicting findings. In this study, we combined whole-brain diffusion tensor imaging and neurofilament light chain (NfL) analysis in blood to reveal potential MDMA-induced axonal neuropathology. To this end, we assessed 39 chronic MDMA users and 39 matched MDMA-naïve healthy controls. MDMA users showed increased fractional anisotropy in several white matter tracts, most prominently in the corpus callosum as well as corticospinal tracts, with these findings partly related to MDMA use intensity. However, the NfL levels of MDMA users were not significantly different from those of controls. We conclude that MDMA use is not associated with significant white matter lesions due to the absence of reduced fractional anisotropy and increased NfL levels commonly observed in conditions associated with white matter lesions, including stimulant and ketamine use disorders. Hence, the MDMA-induced axonal degradation demonstrated in animal models was not observed in this human study of chronic MDMA users.
Insights
This study found no evidence of axonal damage in chronic 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") users, despite animal studies suggesting otherwise. White matter integrity remained intact, indicating MDMA does not cause the axonal neuropathology seen in other substance use disorders.
Area of Science:
- Neuroscience
- Toxicology
- Neuroimaging
Background:
- 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") is a widely used illicit substance.
- Animal studies suggest MDMA can cause axonal degeneration, but human evidence is conflicting.
- Previous human studies on white matter alterations in MDMA users yielded inconsistent results.
Purpose of the Study:
- To investigate potential MDMA-induced axonal neuropathology in chronic human users.
- To combine diffusion tensor imaging (DTI) with blood neurofilament light chain (NfL) analysis.
- To compare white matter integrity and axonal damage markers between MDMA users and controls.
Main Methods:
- Whole-brain diffusion tensor imaging (DTI) was performed on 39 chronic MDMA users and 39 matched controls.
- Blood samples were analyzed for neurofilament light chain (NfL) levels.
- Fractional anisotropy (FA) was assessed in white matter tracts, including the corpus callosum and corticospinal tracts.
Main Results:
- MDMA users exhibited increased fractional anisotropy (FA) in several white matter tracts, notably the corpus callosum and corticospinal tracts.
- These FA changes were partly correlated with MDMA use intensity.
- No significant differences in blood NfL levels were found between MDMA users and controls.
Conclusions:
- MDMA use was not associated with significant white matter lesions in this human study.
- The absence of reduced FA and elevated NfL levels suggests no MDMA-induced axonal degradation.
- Findings contrast with animal models and are distinct from white matter damage observed in other substance use disorders.
